AzTrials
AzTrials

Neonatal Respiratory DistressNCT06292338

Lung Sonar in Neonatal Respiratory Disorders

An observational study of Neonatal Respiratory Distress, run by Gehad Adel Mohammed Hussein.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study aimed to determine the value of chest ultrasonography in comparison to other tools as chest x-ray and ABG in diagnosis and follow up of neonates with respiratory disorders. Read more about this study

Who is it for?
Ages 1 day to 28 days
Conditions the study is for
Neonatal Respiratory Distress
How many people
1 participants
Where
No sites listed yet
Study dates
1 May 2024to 1 May 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 28 days
  • All sexes
  • No healthy volunteers
  • Child

Study population: All neonates (Term and preterm) presented with respiratory disorders

Who may be able to join

  • neonates with a gestational age ≥28 weeks who are suffering from respiratory disorders.

Who cannot join

  • neonates having multiple congenital anomalies, chromosomal aberrations, hydrops fetalis and/or heart failure.

About this study

Official title: A Comparative Study of Lung Ultrasound in Assessment of Neonatal Respiratory Disorders With Other Diagnostic Aids in NICU of Assuit University Children's Hospital

This study aimed to determine the value of chest ultrasonography in comparison to other tools as chest x-ray and ABG in diagnosis and follow up of neonates with respiratory disorders.

Read the detailed description

Respiratory distress is the most frequent cause of neonatal intensive care unit (NICU) admission, and the individual management strategies should be the main task in NICUs for these infants. Fifteen percent of term infants and twenty-nine percent of late preterm infants admitted to the NICU develop significant respiratory morbidity; this is even higher for infants born before 34 weeks' gestation. Neonatal respiratory distress syndrome (NRDS) is one of the most common causes of neonatal respiratory failure and neonatal mortality, especially in premature infants, who tend to have very low birth weight.NRDS is a pulmonary insufficiency caused by structural and functional immaturity of the lung. The incidence of NRDS depends upon gestational age and varies from 92% for infants born at 24-25 weeks to 57% for those born at 30-31 weeks.Mortality from NRDS varies according to the infants' weight, from 50% for infants of <1.0 kg to 0% for those of more than 4.0 kg.Infants affected by NRDS usually require pulmonary surfactant and continuous positive airway pressure (invasive ventilation or mechanical ventilation). Although chest X-Ray plays an important role in diagnosis of respiratory distressed neonates, it leads to their exposure to ionizing radiation due to their small size and the close proximity of radiosensitive tissues and organs are at greater risk from latent effects of chest Xray in comparison to other age groups. As chest x-ray (CXR) and/or chest computerized tomography (chest CT) are the main imaging tools in the diagnosis of lung diseases. For a long time, the lung ultrasound (LUS) was considered a "forbidden zone" in the diagnosis of lung diseases since ultrasonic waves are totally reflected when encountering air. However, by utilizing ultrasonic artefacts formed by different pathological changes in adults, children and poor newborn infants,this "forbidden zone" has been contested and point-of-care lung ultrasound (POC-LUS) has been successfully used for the diagnosis of lung diseases. Neonatal lung ultrasound (LUS) is used in emergent situations, differentiating neonatal respiratory pathologies, and predicting neonatal morbidity . LUS can be brought to the bedside of the fragile neonate, used serially, and does not expose the neonate to ionizing radiation.

Functional and descriptive applications make it a high-fidelity tool to aid in distinguishing the various causes of neonatal respiratory failure and to guide in management . LUS also has increased sensitivity and specificity in comparison with an X-ray for the detection of respiratory pathologies (e.g., TTN , RDS, pmeumothorax, and pleural effusion) and can be utilized to monitor progress of clinical pathologies.The neonatologist-performed LUS has the advantage of being immediately interpreted by those caring for the neonate, potentially leading to more accurate diagnosis and timely therapeutic as intervention. One of the most important applications is the recently proposed use of the LUS score as a semiquantitative assessment of the severity of lung diseases. Efforts have been made to determine the relationship between these scores and the diagnosis of the disease . This study aimed to evaluate the relationship between the LUS score and the diagnosis of neonates hospitalized because of respiratory disorder.

In this study, the investigators also aimed to evaluate the correlation between LUS scores and blood gas parameters in patients hospitalized for respiratory distress and to get an idea about the severity of the disease.Therefore, it can be used to predict the need for surfactants in preterm infants. Its positive role in predicting surfactant need in very- and extremely preterm newborns disease and also the development of chronic lung disease in preterm neonates has been reported recently . LUS scores obtained during the first days of life can provide information about the prognosis of neonatal respiratory failure and predict the need for respiratory support . In addition, LUS performs a useful role in predicting non-invasive ventilation failure in neonates with respiratory distress, and this is important for the clinician to decide to apply invasive mechanical ventilation to prevent clinical deterioration . Lung ultrasound has a prognostic value in monitoring and follow-up of lung development in preterm infants. and it is an adequate tool to predict the development of bronchopulmonary dysplasia (BPD)in infants born preterm before 32 weeks of gestation: for diagnosis of BPD from as early as 3 days post birth, although the optimal timing for its use is 1 week post birth .

The usual evolution of pulmonary patterns in neonates delivered before 32 weeks starts with a pattern characteristic of RDS at birth, with high LUS score values in the 1st days, but then normally improve thereafter as the primary surfactant deciency resolves, reaching LUS score values near 0 at around 1 week post birth.The patients whose LUS scores do not exhibit this decrease or actually increase are more likely to develop BPD.

Keywords
LUS, Neonates, Respiratory disorders
Medical subject headings
Pulmonary Atelectasis, Respiration Disorders

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing between LUS and Chest xRay in neonatal respiratory disorders assessment

    Our study aimed to evaluate the relationship between the LUS score and the diagnosis of neonates hospitalized because of respiratory disorder.

    In our study, we also aimed to evaluate the correlation between LUS scores and blood gas parameters in patients hospitalized for respiratory distress and to get an idea about the severity of the disease.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2024
  2. Study start1 May 2024 (estimated)
  3. Primary completion1 May 2025 (estimated)
  4. Study completion1 May 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
1 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06292338
Sponsor's protocol ID
AUCHAU
Status last verified
Mar 2024
First submitted
27 Feb 2024
Last updated
5 Mar 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Neonatal Respiratory Distress, run by Gehad Adel Mohammed Hussein.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparing between LUS and Chest xRay in neonatal respiratory disorders assessment (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in